Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: A phase I study

Toni Ibrahim, Wainer Zoli, Giovanni Luca Frassineti, Anna Tesei, Ida Colantonio, Manuela Monti, Dino Amadori

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Based on our previous preclinical data, a phase I study was designed to investigate the tolerability of a novel sequence, docetaxel (DOC)-gemcitabine (GEM), in the treatment of non small cell lung cancer (NSCLC). Preclinical study: We evaluated the cytotoxicity of DOC and GEM on NSCLC cell lines and assessed the type of interaction between drug activities following different treatment schemes. Clinical study: Fifteen patients with stage IIIB-IV NSCLC received DOC (day 1) and GEM (days 3 and 8) every 21 days. Dose escalation of both agents was used to identify the maximum tolerated dose. The study was closed at the fifth dose level due to the occurrence of three dose-limiting toxicities: grade 4 febrile neutropoenia, persistent grade 2 fever and grade 3 diarrhoea. The most frequent toxicity was neutropoenia. Non haematological toxicities were diarrhoea, nausea and vomiting, mucositis and alopoecia. Of the 14 evaluable patients, 1 complete response, 4 partial responses, 4 stable diseases and 5 disease progressions were observed. Based on the results of the present study, a phase II trial is ongoing using the fourth dose levels.

Original languageEnglish
Pages (from-to)261-267
Number of pages7
JournalLung Cancer
Volume47
Issue number2
DOIs
Publication statusPublished - Feb 2005

Fingerprint

docetaxel
gemcitabine
Non-Small Cell Lung Carcinoma
Diarrhea
Fever
Mucositis
Maximum Tolerated Dose
Drug Interactions
Nausea
Vomiting
Disease Progression
Therapeutics
Cell Line

Keywords

  • Docetaxel
  • Gemcitabine
  • Phase I study
  • Preclinical data
  • Stage III-IV NSCLC

ASJC Scopus subject areas

  • Oncology

Cite this

@article{379dffef7bbe4e75ae0a30ae49298542,
title = "Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: A phase I study",
abstract = "Based on our previous preclinical data, a phase I study was designed to investigate the tolerability of a novel sequence, docetaxel (DOC)-gemcitabine (GEM), in the treatment of non small cell lung cancer (NSCLC). Preclinical study: We evaluated the cytotoxicity of DOC and GEM on NSCLC cell lines and assessed the type of interaction between drug activities following different treatment schemes. Clinical study: Fifteen patients with stage IIIB-IV NSCLC received DOC (day 1) and GEM (days 3 and 8) every 21 days. Dose escalation of both agents was used to identify the maximum tolerated dose. The study was closed at the fifth dose level due to the occurrence of three dose-limiting toxicities: grade 4 febrile neutropoenia, persistent grade 2 fever and grade 3 diarrhoea. The most frequent toxicity was neutropoenia. Non haematological toxicities were diarrhoea, nausea and vomiting, mucositis and alopoecia. Of the 14 evaluable patients, 1 complete response, 4 partial responses, 4 stable diseases and 5 disease progressions were observed. Based on the results of the present study, a phase II trial is ongoing using the fourth dose levels.",
keywords = "Docetaxel, Gemcitabine, Phase I study, Preclinical data, Stage III-IV NSCLC",
author = "Toni Ibrahim and Wainer Zoli and Frassineti, {Giovanni Luca} and Anna Tesei and Ida Colantonio and Manuela Monti and Dino Amadori",
year = "2005",
month = "2",
doi = "10.1016/j.lungcan.2004.06.011",
language = "English",
volume = "47",
pages = "261--267",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer

T2 - A phase I study

AU - Ibrahim, Toni

AU - Zoli, Wainer

AU - Frassineti, Giovanni Luca

AU - Tesei, Anna

AU - Colantonio, Ida

AU - Monti, Manuela

AU - Amadori, Dino

PY - 2005/2

Y1 - 2005/2

N2 - Based on our previous preclinical data, a phase I study was designed to investigate the tolerability of a novel sequence, docetaxel (DOC)-gemcitabine (GEM), in the treatment of non small cell lung cancer (NSCLC). Preclinical study: We evaluated the cytotoxicity of DOC and GEM on NSCLC cell lines and assessed the type of interaction between drug activities following different treatment schemes. Clinical study: Fifteen patients with stage IIIB-IV NSCLC received DOC (day 1) and GEM (days 3 and 8) every 21 days. Dose escalation of both agents was used to identify the maximum tolerated dose. The study was closed at the fifth dose level due to the occurrence of three dose-limiting toxicities: grade 4 febrile neutropoenia, persistent grade 2 fever and grade 3 diarrhoea. The most frequent toxicity was neutropoenia. Non haematological toxicities were diarrhoea, nausea and vomiting, mucositis and alopoecia. Of the 14 evaluable patients, 1 complete response, 4 partial responses, 4 stable diseases and 5 disease progressions were observed. Based on the results of the present study, a phase II trial is ongoing using the fourth dose levels.

AB - Based on our previous preclinical data, a phase I study was designed to investigate the tolerability of a novel sequence, docetaxel (DOC)-gemcitabine (GEM), in the treatment of non small cell lung cancer (NSCLC). Preclinical study: We evaluated the cytotoxicity of DOC and GEM on NSCLC cell lines and assessed the type of interaction between drug activities following different treatment schemes. Clinical study: Fifteen patients with stage IIIB-IV NSCLC received DOC (day 1) and GEM (days 3 and 8) every 21 days. Dose escalation of both agents was used to identify the maximum tolerated dose. The study was closed at the fifth dose level due to the occurrence of three dose-limiting toxicities: grade 4 febrile neutropoenia, persistent grade 2 fever and grade 3 diarrhoea. The most frequent toxicity was neutropoenia. Non haematological toxicities were diarrhoea, nausea and vomiting, mucositis and alopoecia. Of the 14 evaluable patients, 1 complete response, 4 partial responses, 4 stable diseases and 5 disease progressions were observed. Based on the results of the present study, a phase II trial is ongoing using the fourth dose levels.

KW - Docetaxel

KW - Gemcitabine

KW - Phase I study

KW - Preclinical data

KW - Stage III-IV NSCLC

UR - http://www.scopus.com/inward/record.url?scp=11444256552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11444256552&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2004.06.011

DO - 10.1016/j.lungcan.2004.06.011

M3 - Article

C2 - 15639725

AN - SCOPUS:11444256552

VL - 47

SP - 261

EP - 267

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -